跳至主要内容
临床试验/EUCTR2005-005405-37-CZ
EUCTR2005-005405-37-CZ进行中(未招募)1 期

A multicenter, randomized, open-label dose finding study of RO0503821 in anemic patients with stage IIIB or IV non-small cell lung cancer receiving first line myelosuppressive chemotherapy

F. Hoffmann-La Roche Ltd.0 个研究点目标入组 200 人开始时间: 2006年3月17日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1.Age =18 years
  • 2.Cytologically or histologically confirmed diagnosis of: stage IIIB or IV NSCLC receiving first line myelosuppressive chemotherapy (without planned concurrent thoracic radiotherapy)
  • 3.Hemoglobin =11 g/dL (110 g/L) at screening visit
  • 4.Myelosuppressive chemotherapy scheduled for at least 9 weeks
  • 5.Life expectancy =6 months
  • 6.ECOG performance status 0-2
  • 7.Written informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1.Transfusion of red blood cells during the 4 weeks (28 days) prior to the first planned dose of study medication
  • 2.Radiation therapy to >25% of bone marrow containing areas within the 2 weeks (14 days) prior to the first planned dose of study medication or planned thoracic radiotherapy to be administered concurrently during the study
  • 3.Prior diagnosis of myeloid malignancy
  • 4.Known primary or metastatic malignancy of the central nervous system
  • 5.Uncontrolled hypertension
  • 6.Iron deficiency defined as both transferrin saturation <20% and serum ferritin <100 ng/mL (224 pmol/L)
  • 7.Grade 3/4 thrombocytopenia: platelet count <50 x 109/L
  • 8.Known uncorrected vitamin B12 or folic acid deficiency
  • 9.Prior diagnosis of primary red cell disorders which cause anemia (i.e., hemoglobinopathy, PRCA)
  • 10.Significant hemolysis requiring medical intervention
  • 11.Acute or chronic bleeding requiring therapy within 3 months prior to planned start of study medication (e.g. patients with anemia caused by gastrointestinal bleeding)
  • 12.Acute infection requiring parenteral antibiotic therapy
  • 13.History of seizures within the previous 6 months
  • 14.Pregnancy or breastfeeding
  • 15.Women of child bearing potential without effective contraception

研究者

相似试验

进行中(未招募)
不适用
A multicenter, randomized, open-label dose finding study of RO0503821 in anemic patients with stage IIIB or IV non-small cell lung cancer receiving first line myelosuppressive chemotherapyAnemic patients undergoing chemotherapy
EUCTR2005-005405-37-EEF. Hoffmann-La Roche Ltd.200
进行中(未招募)
不适用
A multicenter, randomized, open-label dose finding study of RO0503821 in anemic patients with stage IIIB or IV non-small cell lung cancer receiving first line myelosuppressive chemotherapyAnemic patients undergoing chemotherapy
EUCTR2005-005405-37-BEF. Hoffmann-La Roche Ltd.200
进行中(未招募)
不适用
A multicenter, randomized, open-label dose finding study of RO0503821 in anemic patients with stage IIIB or IV nonsmall cell lung cancer receiving first line myelosuppressive chemotherapy - NDAnemia in cancer patients receiving chemotherapyMedDRA version: 6.1Level: PTClassification code 10061873
EUCTR2005-005405-37-ITROCHE200
进行中(未招募)
不适用
A multicenter, randomized, open-label dose finding study of RO0503821 in anemic patients with stage IIIB or IV non-small cell lung cancer receiving first line myelosuppressive chemotherapyAnemic patients undergoing chemotherapy
EUCTR2005-005405-37-FIF. Hoffmann-La Roche Ltd.200
进行中(未招募)
不适用
A multicenter, randomized, open-label dose finding study of RO0503821 in anemic patients with stage IIIB or IV non-small cell lung cancer receiving first line myelosuppressive chemotherapyAnemic patients undergoing chemotherapy
EUCTR2005-005405-37-ATF. Hoffmann-La Roche Ltd.200